Core Viewpoint - TianKang (301263.SZ) has received the acceptance notice for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its product pipeline for treating Parkinson's disease [1] Company Summary - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets [1] - The drug is a selective inhibitor of monoamine oxidase B (MAO-B) and is primarily used as an adjunct therapy for adult patients with idiopathic Parkinson's disease (PD) [1] - Safinamide Mesylate Tablets are intended for use in patients experiencing fluctuations in their condition, either alone or in combination with other PD treatments, particularly in the mid to late stages of the disease [1]
泰恩康(301263.SZ)：甲磺酸沙非胺片收到药品注册受理通知书